Baidu
map

Lancet Oncol:吸烟者卵巢癌风险与亚型有关

2012-08-10 奎妮 中国医学论坛报

  8月3日,《柳叶刀·肿瘤学》(Lancet Oncol)在线发表英国一项荟萃分析显示:正在吸烟者卵巢癌的发生率较从不吸烟者轻微增加(RR=1.06,P=0.01),但黏液性卵巢肿瘤的发生率显著增加(RR=1.79,P<0.0001),其中近一半是边缘恶性肿瘤;子宫内膜样腺癌(P=0.001)和透明细胞癌(P=0.03)风险在吸烟者中反而有所降低;未发现浆液性卵巢癌与吸烟存在相关性(P

  8月3日,《柳叶刀·肿瘤学》(Lancet Oncol)在线发表英国一项荟萃分析显示:正在吸烟者卵巢癌的发生率较从不吸烟者轻微增加(RR=1.06,P=0.01),但黏液性卵巢肿瘤的发生率显著增加(RR=1.79,P<0.0001),其中近一半是边缘恶性肿瘤;子宫内膜样腺癌(P=0.001)和透明细胞癌(P=0.03)风险在吸烟者中反而有所降低;未发现浆液性卵巢癌与吸烟存在相关性(P=0.8)。该分析共纳入51项流行病学研究,其中28114例卵巢癌女性,94942名对照者。

链接:Collaborative Group on Epidemiological Studies of Ovarian Cancer.Ovarian cancer and smoking: individual participant meta-analysis including 28 114 women with ovarian cancer from 51 epidemiological studies.The Lancet Oncology, 3 August 2012    

拓展阅读:

Cancer Res:卵巢癌肿瘤或用GD3来抑制抗肿瘤NK细胞的效应

卵巢癌治疗新方案:奈达铂联合紫杉醇化疗

JCO:贝伐单抗对复发性卵巢癌有益

新的卵巢癌诊断检测方法获SFDA批准

2012 NCCN年会:卵巢癌指南仍存争议

第9届国际卵巢癌研讨会:卵巢癌研究热点荟萃

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827441, encodeId=c5d6182e4410b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Feb 14 18:30:00 CST 2013, time=2013-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864374, encodeId=b34618643e432, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed May 15 07:30:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061340, encodeId=74ab206134086, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Jun 03 06:30:00 CST 2013, time=2013-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605072, encodeId=5e5116050e203, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Sun Aug 12 02:30:00 CST 2012, time=2012-08-12, status=1, ipAttribution=)]
    2013-02-14 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1827441, encodeId=c5d6182e4410b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Feb 14 18:30:00 CST 2013, time=2013-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864374, encodeId=b34618643e432, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed May 15 07:30:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061340, encodeId=74ab206134086, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Jun 03 06:30:00 CST 2013, time=2013-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605072, encodeId=5e5116050e203, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Sun Aug 12 02:30:00 CST 2012, time=2012-08-12, status=1, ipAttribution=)]
    2013-05-15 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1827441, encodeId=c5d6182e4410b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Feb 14 18:30:00 CST 2013, time=2013-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864374, encodeId=b34618643e432, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed May 15 07:30:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061340, encodeId=74ab206134086, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Jun 03 06:30:00 CST 2013, time=2013-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605072, encodeId=5e5116050e203, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Sun Aug 12 02:30:00 CST 2012, time=2012-08-12, status=1, ipAttribution=)]
    2013-06-03 sjq027
  4. [GetPortalCommentsPageByObjectIdResponse(id=1827441, encodeId=c5d6182e4410b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Feb 14 18:30:00 CST 2013, time=2013-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864374, encodeId=b34618643e432, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Wed May 15 07:30:00 CST 2013, time=2013-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061340, encodeId=74ab206134086, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Jun 03 06:30:00 CST 2013, time=2013-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605072, encodeId=5e5116050e203, content=<a href='/topic/show?id=5cba39435fd' target=_blank style='color:#2F92EE;'>#吸烟者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39435, encryptionId=5cba39435fd, topicName=吸烟者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc8619318136, createdName=124984e7m89暂无昵称, createdTime=Sun Aug 12 02:30:00 CST 2012, time=2012-08-12, status=1, ipAttribution=)]

相关资讯

JCO:卵巢癌生殖系BRCA1/2测试

近日,科学家建议无论家族史情况如何,诊断患有非黏液性卵巢癌妇女进行生殖系BRCA1/2测试,相关研究论文刊登在Journal of Clinical Oncology杂志上。 为了研究生殖系BRCA1/2突变对卵巢癌的作用,澳大利亚墨尔本东中彼得麦卡勒姆癌症中心Kathryn Alsop等人进行了一项病例对照研究,该研究纳入筛选出的1001名非黏液性卵巢癌妇女,科学家研究分析了生殖系的BRC

Lancet Onco:子宫内膜异位症增加卵巢癌危险

 一些国际研究分析证实,子宫内膜异位症增加侵袭性卵巢癌的发病风险,但并不是所有组织类型的肿瘤风险都增加。该研究结果于2月22日在线发表于《柳叶刀?肿瘤学》(Lancet Oncology.)杂志。   研究人员对卵巢癌联合协会(Ovarian Cancer Association Consortium)中的13项病例对照研究数据进行了汇总。在这些研究中,约有8000名侵袭性卵巢癌妇女和1.3万

卵巢癌治疗新方案:奈达铂联合紫杉醇化疗

       6月30日,中华医学会妇科肿瘤学分会在京发布一项卵巢癌多中心临床试验结果,指出奈达铂联合紫杉醇化疗方案,可明显减少卵巢癌骨髓抑制反应,降低血小板发生率和中重度粒细胞发生率。该研究结果有望为卵巢癌治疗提供新的思路。    目前,外科手术(肿瘤细胞减灭术)+紫杉醇联合卡铂联合化疗(TC)是晚期卵巢癌的标准治疗方案。但由于卡铂骨髓抑制

第9届国际卵巢癌研讨会:卵巢癌研究热点荟萃

 导语:由美国M.D.安德森(Anderson)癌症中心和纽约纪念斯隆-凯特林(Sloan-Kettering)癌症中心联合创立的国际卵巢癌研讨会从1999年伊始,每年分别在两家中心交替召开,就卵巢癌相关问题和最新进展进行研讨。第9届国际卵巢癌研讨会于2011年12月在M.D.Anderson癌症中心召开,本次会议共设置了包括卵巢癌筛查、罕见卵巢肿瘤相关问题、手术争论、新的影像学检查、新

2012 NCCN年会:NCCN肿瘤指南更新要点汇总

       肺癌指南 更新多        今年非小细胞肺癌指南更新颇多,包括对电视胸腔镜手术(VATS)、新药Crizotinib的推荐以及修订腺癌分期等。        分期推荐:EUS/EBUS及原位腺癌       &nb

Anticancer Research:cfDNA示晚期卵巢癌预后

     《抗癌研究》(Anticancer Research)杂志近期发表的一项研究提示,术前血清RAS癌基因家族成员(RAB25)无细胞DNA(cfDNA)水平可能是预测晚期卵巢癌患者生存预后的一个有用的生物标志物。   此前研究已经评估了cfDNA作为一种非侵袭性生物标志物在多种癌症中的应用价值。该研究旨在评估cfDNA水平对卵巢癌的预后价值。   研究检测了36例卵巢癌和1

Baidu
map
Baidu
map
Baidu
map